Molecular Partners Ag (MOLN) Income towards Parent Company (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Income towards Parent Company of -$16792.1 for Q1 2026, up 10.0% year-over-year from -$15266.2 in Q1 2025, and up 99.98% quarter-over-quarter from -$81.8 million in Q4 2025.
Molecular Partners Ag (MOLN) Income towards Parent Company (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Income towards Parent Company for 7 consecutive years, with -$16792.1 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income towards Parent Company rose 10.0% year-over-year to -$16792.1; the TTM figure through Mar 2026 stood at -$81.9 million (down 31.54% YoY), while the FY2025 annual figure was $100.5 million, down 37.84% from the prior year.
- Income towards Parent Company improved to -$16792.1 in Q1 2026 per MOLN's latest filing, from -$81.8 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $127.7 million in Q4 2022 and bottomed at -$81.8 million in Q4 2025.
- Historically, Income towards Parent Company has averaged -$6.5 million across 5 years, with a median of -$16792.1 in 2026.
- Annual changes were most pronounced in 2022 — Income towards Parent Company surged 1005.54% — and 2023, when it tumbled 278.7%.
- Molecular Partners Ag's Income towards Parent Company stood at $127.7 million in 2022, then tumbled by 156.44% to -$72.1 million in 2023, then gained by 13.69% to -$62.2 million in 2024, then plunged by 31.56% to -$81.8 million in 2025, then surged by 99.98% to -$16792.1 in 2026.
- Business Quant data shows MOLN's Income towards Parent Company at -$16792.1 in Q1 2026, -$81.8 million in Q4 2025, and -$14803.3 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16,792.10 |
| Dec 31, 2025 | -81.84 Mn |
| Sep 30, 2025 | -14,803.30 |
| Jun 30, 2025 | -24,645.31 |
| Mar 31, 2025 | -18,656.89 |
| Dec 31, 2024 | -62.21 Mn |
| Sep 30, 2024 | -18,940.19 |
| Jun 30, 2024 | -16,677.58 |
| Mar 31, 2024 | -12,981.38 |
| Dec 31, 2023 | -72.07 Mn |
| Sep 30, 2023 | -12,957.15 |
| Jun 30, 2023 | -17.78 Mn |
| Mar 31, 2023 | -15,983.58 |
| Dec 31, 2022 | 127.71 Mn |
| Sep 30, 2022 | -13,800.36 |
| Jun 30, 2022 | -4.70 Mn |
| Mar 31, 2022 | 165,800.92 |
| Dec 31, 2021 | -69.13 Mn |
| Sep 30, 2021 | -13,411.64 |
| Jun 30, 2021 | -36.79 Mn |